Your browser doesn't support javascript.
loading
[An unusual digestive complication under anti-PD-1 (pembrolizumab)]. / Une complication digestive rare sous anti-PD-1 (pembrolizumab).
Calvani, Julien; Elia, Rémie; Battistella, Maxime; Delyon, Julie; Vivier-Chicoteau, Justine; Gornet, Jean-Marc; Lebbé, Céleste; Baroudjian, Barouyr; Bertheau, Philippe.
Afiliação
  • Calvani J; Département de pathologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: julien.calvani@aphp.fr.
  • Elia R; Département de pathologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Battistella M; Département de pathologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; Inserm U976, Paris, France; Groupe PATIO, partage d'expérience autour des toxicités des immunothérapies en oncologie, hôpital Saint-Louis, Paris, France.
  • Delyon J; Inserm U976, Paris, France; Groupe PATIO, partage d'expérience autour des toxicités des immunothérapies en oncologie, hôpital Saint-Louis, Paris, France; Département de dermatologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Vivier-Chicoteau J; Département de gastroentérologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Gornet JM; Département de gastroentérologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Lebbé C; Inserm U976, Paris, France; Groupe PATIO, partage d'expérience autour des toxicités des immunothérapies en oncologie, hôpital Saint-Louis, Paris, France; Département de dermatologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Baroudjian B; Groupe PATIO, partage d'expérience autour des toxicités des immunothérapies en oncologie, hôpital Saint-Louis, Paris, France; Département de dermatologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Bertheau P; Département de pathologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; Inserm U976, Paris, France.
Ann Pathol ; 40(4): 320-323, 2020 Jul.
Article em Fr | MEDLINE | ID: mdl-32107038
ABSTRACT
The most commonly reported pattern of anti-PD-1 induced colitis is an active colitis characterized by neutrophilic inflammation and prominent apoptosis. On the other hand, reports of collagenous colitis (which is a microscopic colitis) are exceptional. In this report, we describe an unusual case of anti-PD1-associated collagenous colitis in a 76-year-old man, treated with pembrolizumab for a stage IV cutaneous melanoma. Fourteen months after the start of pembrolizumab, the patient developed a grade 3 diarrhea (up to 9 stools per day) associated with profound hypokalemia. No bacterial, viral or parasitological infectious agents were found from stool analysis. The rectosigmoidoscopy showed colonic diffuse congestion with no ulceration. Systematic biopsies were performed during endoscopy. Histologically, the fragments analyzed revealed a moderately thickened subepithelial collagen layer (20-30µm thick) associated with a mild mixed inflammatory infiltrate within the lamina propria. There were no granuloma lesions, ulcerations or viral inclusion bodies. The patient was initially successfully treated with corticosteroids (prednisone) and temporary interruption of pembrolizumab. However, during corticosteroids tapering, a relapse was observed. The treatment was switched to budesonide, leading to a complete and definitive resolution of diarrhea. To date, budesonide has been stopped and pembrolizumab has not been restarted. Currently, there is a bone progression treated by radiotherapy alone. In case of a more important progression, a systemic treatment will be secondarily discussed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Colite Colagenosa / Anticorpos Monoclonais Humanizados / Melanoma Limite: Aged / Humans / Male Idioma: Fr Revista: Ann Pathol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Colite Colagenosa / Anticorpos Monoclonais Humanizados / Melanoma Limite: Aged / Humans / Male Idioma: Fr Revista: Ann Pathol Ano de publicação: 2020 Tipo de documento: Article